These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1711585)

  • 21. Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.
    Urasaki Y; Ueda T; Nakamura T
    Jpn J Cancer Res; 1994 Jun; 85(6):659-64. PubMed ID: 7914886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
    Trouet A; Masquelier M; Baurain R; Deprez-De Campeneere D
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):626-9. PubMed ID: 6952214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
    Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
    Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
    Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
    Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism].
    Zhang XJ; Wen L; Wang FX; Luo JM; Pan L; Liu XJ; DU XY; Dong ZR; Yang SF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1123-8. PubMed ID: 17204177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].
    Jiang HN; Liu ZG; Hu R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1342-1349. PubMed ID: 29070105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
    Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
    Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
    Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
    Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
    Van Acker KL; Van Hove LM; Boogaerts MA
    Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
    Ni S; Stephenson SM; Lee RJ
    Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.
    Fishwild DM; Wu HM; Carroll SF; Bernhard SL
    Clin Exp Immunol; 1994 Jul; 97(1):10-8. PubMed ID: 8033405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
    Chauvier D; Morjani H; Manfait M
    Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Nissen NI
    Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
    Zhang G; Fang L; Zhu L; Zhong Y; Wang PG; Sun D
    J Med Chem; 2006 Mar; 49(5):1792-9. PubMed ID: 16509594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
    Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
    Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
    Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
    Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Lemez P; Maresová J
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.